Hematologist-Oncologist: Wang, MD | Loyola Medicine

UPDATE: Power outages caused by storms have been resolved at Palos Health South Campus, Elmhurst and River Forest outpatient clinics. Palos Health South Campus has resumed appointments as scheduled. Immediate Care at River Forest will reopen today, August 12, 2020, beginning at noon. Appointments at the Elmhurst clinic will resume as scheduled on Friday, August 14.

COVID-19 (Coronavirus) Update: Learn More About Loyola Medicine Care During COVID-19.

Wang, MD

Medicine

Hematology/Oncology
Assistant Professor

Languages Spoken

English
<

Clinical Expertise

  • Head And Neck Cancer
  • Lung Cancer

About Dr. Wang

Interests

Medical Education

Medical School
University of Iowa
Residency
St. Mary Medical Center - Internal Medicine
Loyola University Medical Center - Internal Medicine
Fellowship
  • Loyola University Medical Center/Oncology Institute - Hematology & Medical Oncology

Board Certification

American Board of Internal Medicine
American Board of Internal Medicine Subspecialty Medical Oncology

Research

  • Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells. Moore, T; Wagner, CR; Scurti, GM; Hutchens, KA; Godellas, C; Clark, AL; Kolawole, EM; Hellman, LM; Singh, NK; Huyke, FA; Wang, SY; Calabrese, KM; Embree, HD; Orentas, R; Shirai, K; Dellacecca, E; Garrett-Mayer, E; Li, M; Eby, JM; Stiff, PJ; Evavold, BD; Baker, BM; Le Poole, IC; Dropulic, B; Clark, JI; Nishimura, MI, Cancer immunology, immunotherapy : CII
  • Correction to: Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells. Moore, T; Wagner, CR; Scurti, GM; Hutchens, KA; Godellas, C; Clark, AL; Kolawole, EM; Hellman, LM; Singh, NK; Huyke, FA; Wang, SY; Calabrese, KM; Embree, HD; Orentas, R; Shirai, K; Dellacecca, E; Garrett-Mayer, E; Li, M; Eby, JM; Stiff, PJ; Evavold, BD; Baker, BM; Le Poole, IC; Dropulic, B; Clark, JI; Nishimura, MI, Cancer immunology, immunotherapy : CII
  • Limited ability of existing nomograms to predict outcomes in men undergoing active surveillance for prostate cancer. Wang, SY; Cowan, JE; Cary, KC; Chan, JM; Carroll, PR; Cooperberg, MR, BJU international
View All ResearchShow Less
  • miR-19 miR-345, miR-519c-5p serum levels predict adverse pathology in prostate cancer patients eligible for active surveillance., Wang, SY; Shiboski, S; Belair, CD; Cooperberg, MR; Simko, JP; Stoppler, H; Cowan, J; Carroll, PR; Blelloch, R, PLoS ONE